Search Results - "Donk, N"

Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab by Nijhof, I S, Groen, R W J, Lokhorst, H M, van Kessel, B, Bloem, A C, van Velzen, J, de Jong-Korlaar, R, Yuan, H, Noort, W A, Klein, S K, Martens, A C M, Doshi, P, Sasser, K, Mutis, T, van de Donk, N W C J

“…Daratumumab is an anti-CD38 monoclonal antibody with lytic activity against multiple myeloma (MM) cells, including ADCC (antibody-dependent cellular…”
Get full text

Characterization of dysgeusia and xerostomia in patients with multiple myeloma treated with the T-cell redirecting GPRC5D bispecific antibody talquetamab by Laheij, A. M. G. A., van de Donk, N. W. C. J.

“…Purpose In recent years, various immunotherapies have improved the survival of patients with multiple myeloma (MM). However, there remains an unmet need for…”
Get full text

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma by Lokhorst, Henk M, Plesner, Torben, Laubach, Jacob P, Nahi, Hareth, Gimsing, Peter, Hansson, Markus, Minnema, Monique C, Lassen, Ulrik, Krejcik, Jakub, Palumbo, Antonio, van de Donk, Niels W.C.J, Ahmadi, Tahamtan, Khan, Imran, Uhlar, Clarissa M, Wang, Jianping, Sasser, A. Kate, Losic, Nedjad, Lisby, Steen, Basse, Linda, Brun, Nikolai, Richardson, Paul G

“…Daratumumab was associated with impressive antitumor responses, including complete and very good partial responses, in heavily pretreated patients with…”
Get full text

Treatment sequences and drug costs from diagnosis to death in multiple myeloma by Seefat, M. R., Cucchi, D. G. J., Groen, K., Donker, M. L., Hem, K. G., Westerman, M., Gerrits, A. M., Beeker, A., Donk, N. W. C. J., Blommestein, H. M., Zweegman, S.

“…Novel therapies for multiple myeloma (MM) have improved patient survival, but their high costs strain healthcare budgets. End‐of‐life phases of treatment are…”
Get full text

Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma by van de Donk, N. W. C. J., Mutis, T., Poddighe, P. J., Lokhorst, H. M., Zweegman, S.

“…Summary Monoclonal gammopathy of undetermined significance (MGUS) is one of the most common premalignant disorders. IgG and IgA MGUS are precursor conditions…”
Get full text

Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma by van de Donk, N W C J, Kamps, S, Mutis, T, Lokhorst, H M

“…The introduction of autologous stem cell transplantation combined with the introduction of immunomodulatory drugs (IMiDs) and proteasome inhibitors has…”
Get full text

Effect of conditioning regimens on graft failure in myelofibrosis: a retrospective analysis by Slot, S, Smits, K, van de Donk, N W C J, Witte, B I, Raymakers, R, Janssen, J J W M, Broers, A E C, te Boekhorst, P A W, Zweegman, S

“…In myelofibrosis, the introduction of reduced-intensity conditioning (RIC) preceding allogeneic stem cell transplantation (SCT) resulted in lower…”
Get full text

Monoclonal gammopathy of renal significance (MGRS) histopathologic classification, diagnostic workup, and therapeutic options by Amaador, K, Peeters, H, Minnema, M C, Nguyen, T Q, Dendooven, A, Vos, J M I, Croockewit, A J, van de Donk, N W C J, Jacobs, J F M, Wetzels, J F M, Sprangers, B, Abrahams, A C

“…Monoclonal gammopathy of renal significance (MGRS) includes all kidney disorders caused by a monoclonal protein (M-protein) secreted by a small plasma cell…”
Get full text

A phase I/II minor histocompatibility antigen-loaded dendritic cell vaccination trial to safely improve the efficacy of donor lymphocyte infusions in myeloma by Franssen, L E, Roeven, M W H, Hobo, W, Doorn, R, Oostvogels, R, Falkenburg, J H F, van de Donk, N W, Kester, M G D, Fredrix, H, Westinga, K, Slaper-Cortenbach, I, Spierings, E, Kersten, M J, Dolstra, H, Mutis, T, Schaap, N, Lokhorst, H M

“…Allogeneic stem cell transplantation (allo-SCT) with or without donor lymphocyte infusions (DLI) is the only curative option for several hematological…”
Get full text

Case report: persistently seronegative neuroborreliosis in an immunocompromised patient by Wagemakers, A, Visser, M C, de Wever, B, Hovius, J W, van de Donk, N W C J, Hendriks, E J, Peferoen, L, Muller, F F, Ang, C W

“…Infection with Borrelia burgdorferi sensu lato complex (B. b. sl) spirochetes can cause Lyme borreliosis, manifesting as localized infection (e.g. erythema…”
Get full text

The impact of circulating suppressor cells in multiple myeloma patients on clinical outcome of DLIs by Franssen, L E, van de Donk, N W C J, Emmelot, M E, Roeven, M W H, Schaap, N, Dolstra, H, Hobo, W, Lokhorst, H M, Mutis, T

“…Allo-SCT followed by DLIs can establish long-term remissions in multiple myeloma (MM) patients. In many patients, however, the immunotherapeutic…”
Get full text

Quality of life gains in frail and intermediate-fit patients with multiple Myeloma: Findings from the prospective HOVON123 clinical trial by Seefat, M.R., Stege, C.A.M., Lissenberg-Witte, B.I., Levin, M.D., Timmers, G.J., Hoogendoorn, M., Ypma, P.F., Klein, S.K., Velders, G.A., Westerman, M., Strobbe, L., Durdu-Rayman, N., Davidis-van Schoonhoven, M.A., van Kampen, R.J.W., Dijk, A.C., Koster, A., Silbermann, M.H., van der Spek, E., Beeker, A., Erjavec, Z., de Graauw, N.C.H.P., Leys, M.B.L., Sonneveld, P., van de Donk, N.W.C.J., Nasserinejad, K., Blommestein, H.M., Cucchi, D.G.J., Zweegman, S.

“…Frailty in newly-diagnosed multiple myeloma (NDMM) patients is associated with treatment-related toxicity, which negatively affects health-related quality of…”
Get full text

Carfilzomib for relapsed and refractory multiple myeloma by Groen, K, van de Donk, Nwcj, Stege, Cam, Zweegman, S, Nijhof, I S

“…Although the prognosis of multiple myeloma (MM) patients has dramatically improved during recent years, virtually all patients eventually develop relapsed…”
Get full text

P18 SKIN EXPRESSION OF P16INK4A, A BIOMARKER FOR CELLULAR SENESCENCE, DOES NOT PREDICT FRAILTY OR TREATMENT OUTCOME IN NEWLY DIAGNOSED MULTIPLE MYELOMA by Smits, F., Groen, K., Stege, C., Seefat, M., Nijhof, I., Donk, N., Ypma, P., Zweegman, S.

Get full text

Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma by VAN DE DONK, N. W. C. J, KRÖGER, N, AYUK, F. A, VAN OERS, M. H. J, NAGLER, A, VERDONCK, L. F, LOKHORST, H. M, HEGENBART, U, CORRADINI, P, SAN MIGUEL, J. F, GOLDSCHMIDT, H, PEREZ-SIMON, J. A, ZIJIMANS, M, RAYMAKERS, R. A, MONTEFUSCO, V

“…In this retrospective study, we evaluated donor lymphocyte infusions given for relapsed (n=48) or persistent (n=15) myeloma following non-myeloablative…”
Get full text

P53 REAL‐WORLD TREATMENT SEQUENCES AND COSTS OF 96 PATIENTS WITH MULTIPLE MYELOMA FROM DIAGNOSIS TO DEATH by Seefat, M.R., Cucchi, D.G.J., Groen, K., Donker, M.L., Hem, K.G., Westerman, M., Gerrits, A.M., Beeker, A., Donk, N., Blommestein, H.M., Zweegman, S.

Get full text

Primary Plasma Cell Leukemia by van de Donk, N

Get full text

Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome by Minnema, M C, van de Donk, N W C J, Zweegman, S, Hegenbart, U, Schonland, S, Raymakers, R, Zijlmans, J M J M, Kersten, M J, Bos, G M J, Lokhorst, H M

“…Recent literature suggests that after non-myeloablative allogeneic (NMA) stem cell transplantation (SCT), the incidence of extramedullary (EM) relapse in…”
Get full text

P1739: HEALTH‐RELATED QUALITY OF LIFE IN PATIENTS WITH TRIPLE‐CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH IBERDOMIDE PLUS DEXAMETHASONE IN A PHASE 1B/2A OPEN‐LABEL DOSE ESCALATION STUDY by Donk, N. W., Guo, S., Shi, L., Lord‐Bessen, J., Tang, D., Karlin, L., Weisel, K., Ramasamy, K., Abad, P. C., Amin, A., Amin, S., Lonial, S.

Get full text

P865: BIOMARKER ANALYSIS TO SUPPORT DOSE OPTIMIZATION OF IBERDOMIDE AS MONOTHERAPY AND IN COMBINATION WITH STANDARD OF CARE TREATMENTS FOR MULTIPLE MYELOMA FROM A PHASE 1/2 TRIAL by Amatangelo, M., Cheng, Y., Pierceall, W., Donk, N. W., Lonial, S., Wang, M., Emerson, J., Hong, K., Maciag, P., Peluso, T., Gandhi, A., Thakurta, A.

Get full text